The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol
Abstract Background Pyrazinamide (PZA) is a key component of current and future regimens for tuberculosis (TB). Inclusion of PZA at higher doses and for longer durations may improve efficacy outcomes but must be balanced against the potential for worse safety outcomes. Methods We will search for ran...
Main Authors: | James D. Millard, Elizabeth A. Mackay, Laura J. Bonnett, Geraint R. Davies |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | Systematic Reviews |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13643-019-1231-1 |
Similar Items
-
Activity of Pyrazinamide against <i>Mycobacterium tuberculosis</i> at Neutral pH in PZA-S1 Minimal Medium
by: Wanliang Shi
Published: (2021-07-01) -
Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates<subtitle>PncA mutations and PZA resistance in M. tuberculosis in Vietnam</subtitle>
by: Nguyen Quang Huy, et al.
Published: (2017-01-01) -
Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients
by: Rong Li, et al.
Published: (2023-06-01) -
Detection of pyrazinamide heteroresistance in Mycobacterium tuberculosis
by: Mikaela Glader, et al.
Published: (2015-01-01) -
Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan
by: Hsin-Ting Huang, et al.
Published: (2023-12-01)